(2-methoxy-6-nitrophenyl)methanol | 19689-87-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-methoxy-6-nitrophenyl)methanol
• 英文别名: 2-Nitro-6-methoxy-benzylalkohol；2-methoxy-6-nitro-benzyl alcohol；2-Methoxy-6-nitro-benzylalkohol
• CAS: 19689-87-3
• 化学式: C₈H₉NO₄
• mdl: MFCD09831916
• 分子量: 183.164
• InChiKey: PMBQOGLGGKPTMQ-UHFFFAOYSA-N

物化性质

• 沸点：
  327.3±27.0 °C(Predicted)
• 密度：
  1.316±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  75.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-methoxy-6-nitrophenyl)methanol 在 palladium on activated charcoal 2,6-二甲基吡啶 、 氢氧化钾 、 sodium hydroxide 、 锂硼氢 、 chiral cinchonidine-derived salt 、 氢气 、 三溴化磷 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Synthesis of 7,8-disubstituted benzolactam-V8 and its binding to protein kinase C

  摘要：

  7-Methoxy-8-decynyl-benzolactam 4 is synthesized using a catalytic asymmetric alkylation reaction as a key step. This compound shows potent activity to three PKC isozymes tested (K-i = 45.6, 91.1, and 121.3 nM to PKC alpha, delta, and epsilon, respectively), indicating that introduction of a suitable substituent at the 7-position of 8-decynyl-benzolactam-V8 only slightly reduces the PKC binding affinity. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00609-0
• 作为产物：
  描述：

  2-甲氧基-6-硝基苯甲酸 在 氯化亚砜 作用下， 生成 (2-methoxy-6-nitrophenyl)methanol
  参考文献：
  名称：

  Tomita; Hirai, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1959, vol. 79, p. 723,726

  摘要：

  DOI：

文献信息

• [EN] ALLOSTERIC ACTIVATORS OF THE ALPHA1A -ADRENERGIC RECEPTOR<br/>[FR] ACTIVATEURS ALLOSTÉRIQUES DU RÉCEPTEUR ALPHA1A-ADRÉNERGIQUE
  申请人：CLEVELAND CLINIC FOUND

  公开号：WO2020219720A1

  公开（公告）日：2020-10-29

  The present invention relates to compounds that are activators of the Alpha1A-Adrenergic Receptor (α1A-AR) and methods of using such compounds: for treating neurological conditions, for cardio-protection, and for treating other conditions. In certain embodiments, the α1A-AR activator compound is a compound of Formula I. In certain embodiments, the neurological condition is Alzheimer's disease, benign prostatic hyperplasia, memory loss, depression, or Parkinson's disease.

  本发明涉及激活Alpha1A-肾上腺素受体（α1A-AR）的化合物及使用这些化合物的方法：用于治疗神经系统疾病、心脏保护和治疗其他疾病。在某些实施例中，α1A-AR激活剂化合物是式I的化合物。在某些实施例中，神经系统疾病是阿尔茨海默病、良性前列腺增生、记忆力下降、抑郁症或帕金森病。
• [EN] SYNTHESIS OF INDOLE-CONTAINING SPLA2 INHIBITORS<br/>[FR] SYNTHESE D'INHIBITEURS SPLA2 A TENEUR EN INDOLE
  申请人：LILLY CO ELI

  公开号：WO2001044184A1

  公开（公告）日：2001-06-21

  A method of making a compound include reacting a compound represented by formula (I), with a base, to form the compound of formula (II); and where R1 is H, R10 or -C(O)R10; R2 is R20 -OR20, -SR20, -NR20R20' or -C(O)R20;R3, R4, R5, R6 and R7 are each individually H, halogen, R, -OR, -SR, -NRR', -C(O)R, -C(O)OR, -S(O)R or -S(O)2R; provided that at least one of R4 and R5 is not H; each R, R10 and R20 is individually alkyl, alkenyl, alkynyl, aryl or heterocyclic radical; each R' and R20' is individually H, alkyl, alkenyl, alkynyl, aryl or heterocyclic radical; and W is a trisubstituted phosphorous. The method provides an alternative route to indole-3-glyoxylamide compounds.

  一种制备化合物的方法包括将式(I)所表示的化合物与碱反应，形成式(II)的化合物；其中R1为H，R10或-C（O）R10；R2为R20-OR20，-SR20，-NR20R20'或-C（O）R20；R3，R4，R5，R6和R7各自为H，卤素，R，-OR，-SR，-NRR'，-C（O）R，-C（O）OR，-S（O）R或-S（O）2R；前提是R4和R5中至少有一个不是H；每个R，R10和R20分别是烷基，烯基，炔基，芳基或杂环基；每个R'和R20'分别为H，烷基，烯基，炔基，芳基或杂环基；W为三取代磷。该方法提供了一种合成吲哚-3-甘氧酰胺化合物的替代路线。
• Plant antitumor agents. II. Structure of two new alkaloids from Camptotheca acuminata
  作者：Mansukhlal C. Wani、Monroe E. Wall

  DOI：10.1021/jo01257a036

  日期：1969.5
• 8-HYDROCARBYL SUBSTITUTED BENZODIZOCINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN KINASE C (=PKC) MODULATORS
  申请人：GEORGETOWN UNIVERSITY

  公开号：EP0918757A1

  公开（公告）日：1999-06-02
• ALLOSTERIC ACTIVATORS OF THE ALPHA1A-ADRENERGIC RECEPTOR
  申请人：The Clevland clinic Foundatio

  公开号：US20220227717A1

  公开（公告）日：2022-07-21

  The present invention relates to compounds that are activators of the Alpha 1A -Adrenergic Receptor (α 1A -AR) and methods of using such compounds: for treating neurological conditions, for cardio-protection, and for treating other conditions. In certain embodiments, the α 1A -AR activator compound is a compound of Formula I. In certain embodiments, the neurological condition is Alzheimer's disease, benign prostatic hyperplasia, memory loss, depression, or Parkinson's disease.